Printer Friendly

ALLIANCE PHARMACEUTICAL CORP. ANNOUNCES MODIFICATION TO MARKETING AGREEMENT

 SAN DIEGO, June 7 /PRNewswire/ -- Alliance Pharmaceutical Corp. (NASDAQ: ALLP) (Alliance) and Boehringer Ingelheim International GmbH (BII) announced that they have agreed to modify the terms of the marketing agreement between the companies. In May 1989, Alliance and BII entered into a marketing agreement pursuant to which Alliance and BII would share the worldwide clinical development of certain perfluorochemical products for use as contrast agents and as a temporary blood substitute. BII had the right to obtain regulatory approval and to market these products outside of North America. In North America, Alliance has commenced or completed clinical trials on four of these products while no studies have begun in the rest of the world. The modifications to the agreement will provide that Alliance will conduct clinical trials and direct regulatory approval processes on a worldwide basis and further grants Alliance an option to reacquire BII's marketing rights for the products.
 According to Duane Roth, chairman and chief executive officer of Alliance, "This modification will allow Alliance to control the regulatory approval strategies of the products on a worldwide basis. Over the past four years, Alliance has developed considerable expertise and knowledge of the perflourochemical-based products and, at this point, can more efficiently manage the regulatory and clinical process than was contemplated by the 1989 agreement. In addition, the modification to our agreement will provide Alliance with the flexibility to reacquire the marketing rights to these products." Roth also noted that the relationship with BII has been and continues to be constructive and that over the years, Alliance has gained considerable knowledge from this collaboration.
 Engelbert Gunster, manager of International Hospital Products for BII and a director of Alliance, stated, "Due to changes in priority, these products do not fit exactly with the development strategy of our core medical products today, and therefore BII's emphasis and commitment to the development of the perfluorchemical products is not at the level that was originally anticipated. We feel that these products can be developed more effectively by Alliance at this time. We remain optimistic about the development of the products and their medical utility."
 The 1989 marketing agreement called for BII to make annual research payments of approximately $1.5 million. Under the terms of the modification, BII will discontinue these payments effective July 1, 1993. In exchange, Alliance will have the option to purchase the approximately 950,000 shares of Alliance stock owned by BII until July 1, 1995. The marketing agreement will terminate upon BII's disposition of any shares, whether pursuant to the option or otherwise.
 Boehringer Ingelheim International GmbH is a German-headquartered pharmaceutical company with world-wide operations. Its research has focused on therapeutic products for treatment of cardiovascular and pulmonary diseases, gastrointestinal disorders and illnesses of the central nervous system, imunological and inflammatory diseases and viral infections.
 Alliance Pharmaceutical Corp. is located in San Diego, and is a leader in the development of proprietary pharmaceutical products for use as diagnostic contrast agents and oxygen carriers, based upon perfluorchemical and emulsion technologies.
 -0- 6/7/93
 /CONTACT: Stuart Gauld, VP-investor relations, 619-558-4300/
 (ALLP)


CO: Alliance Pharmaceutical Corp.; Boehringer Ingelheim
 International GmbH ST: California IN: MTC SU:


BP-EH -- SD006 -- 6252 06/07/93 17:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 7, 1993
Words:533
Previous Article:LADBROKE RACING: PENNSYLVANIA GOVERNOR SIGNS SIMULCASTING BILL
Next Article:FORD VEHICLE SALES ARE 'HOT' IN FLORIDA
Topics:


Related Articles
AMERICAN HOME PRODUCTS AND ELI LILLY AND COMPANY ANNOUNCE MARKETING AGREEMENT
MARION MERRELL DOW INC. AND MITSUBISHI KASEI CORP. ANNOUNCE NORTH AMERICAN COLLABORATION
AGOURON AND SYNTEX TO COLLABORATE IN ARTHRITIS AND CANCER DRUG DISCOVERY
DURAMED ANNOUNCES ESTROPIPATE INTRODUCTION
DURAMED ANNOUNCES ESTROPIPATE INTRODUCTION
ALLIANCE PHARMACEUTICAL CORP. REGAINS MARKETING RIGHTS
DURA PHARMACEUTICALS INC. AND DURA DELIVERY SYSTEMS INC. ANNOUNCE A LICENSE AND SUPPLY AGREEMENT WITH MITSUBISHI CHEMICAL CORP.
UNIHOLDING CORP. ANNOUNCES EXPANSION OF SERVICES
CARACO AND APOTEX USA ANNOUNCE ANDA FILING
IVAX And Knoll Establish New Business Alliance In Europe

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters